On Monday, Atossa Therapeutics Inc (NASDAQ: ATOS) opened higher 4.92% from the last session, before settling in for the closing price of $1.22. Price fluctuations for ATOS have ranged from $0.70 to $2.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 11.46% at the time writing. With a float of $125.75 million, this company’s outstanding shares have now reached $125.80 million.
Let’s determine the extent of company efficiency that accounts for 12 employees. In terms of profitability, gross margin is -27.78%, operating margin of -163827.78%, and the pretax margin is -149505.56%.
Atossa Therapeutics Inc (ATOS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atossa Therapeutics Inc is 0.04%, while institutional ownership is 21.86%. The most recent insider transaction that took place on Apr 10 ’24, was worth 44,250. In this transaction Director of this company bought 25,000 shares at a rate of $1.77, taking the stock ownership to the 25,000 shares.
Atossa Therapeutics Inc (ATOS) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.06 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.06) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.46% per share during the next fiscal year.
Atossa Therapeutics Inc (NASDAQ: ATOS) Trading Performance Indicators
Check out the current performance indicators for Atossa Therapeutics Inc (ATOS). In the past quarter, the stock posted a quick ratio of 13.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Atossa Therapeutics Inc (ATOS)
Looking closely at Atossa Therapeutics Inc (NASDAQ: ATOS), its last 5-days average volume was 0.98 million, which is a drop from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic %D was 15.54%. Additionally, its Average True Range was 0.08.
During the past 100 days, Atossa Therapeutics Inc’s (ATOS) raw stochastic average was set at 33.33%, which indicates a significant increase from 22.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.74% in the past 14 days, which was higher than the 58.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4144, while its 200-day Moving Average is $1.3808. However, in the short run, Atossa Therapeutics Inc’s stock first resistance to watch stands at $1.3433. Second resistance stands at $1.4067. The third major resistance level sits at $1.4533. If the price goes on to break the first support level at $1.2333, it is likely to go to the next support level at $1.1867. Should the price break the second support level, the third support level stands at $1.1233.
Atossa Therapeutics Inc (NASDAQ: ATOS) Key Stats
There are currently 125,801K shares outstanding in the company with a market cap of 165.09 million. Presently, the company’s annual sales total 0 K according to its annual income of -30,090 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -7,230 K.
